Old TB vaccine shows promise for type 1 diabetes control
NCT ID NCT02081326
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether repeated doses of the BCG vaccine (originally for tuberculosis) can help adults with long-standing type 1 diabetes lower their blood sugar levels. About 150 participants receive either BCG or a placebo over 5 years, with follow-up for 10 years. The goal is to see if BCG can improve sugar control even when the pancreas has little function left, and also protect against infections like COVID-19.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Immunobiology Labs CNY 149
Charlestown, Massachusetts, 02129, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a different way of pedaling rebuild muscles after severe COVID-19?
- Ancient herbs take on long COVID: a trial tests whether chinese medicine can soothe persistent fatigue
- Can a 15-Minute chat at a testing site boost COVID-19 vaccination?
- E-Ink screens in ERs could boost patient satisfaction
- Massive study tracks how lockdowns shaped mental health across america
- Hidden danger: study probes blood clot risk in cancer patients with COVID-19